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1. Introduction  
Myocarditis is the term used to describe acute or chronic inflammation of the 
myocardium. For two decades, there has been increasing confrontations concerning the 
diagnosis, management and clinical outcome of the myocarditis. The cause of myocarditis 
frequently remains unknown. However, infections, systemic diseases, toxins and drugs 
have been reported being associated with inflammation of the myocardium (Kearney et 
al., 2001 & Mahrholdt H et al, 2006). The majority of cases  are supposed to be due to 
infectious agents and it was recognized that any infectious agents could initiate 
myocarditis (Brodison & Swann, 2001). In North America and Europe, viral infection is 
the most common causes of myocarditis (Magnani & Dec, 2006). The true overall 
incidence of myocarditis remain obscure due to inconsistency of its definition and clinical 
manifestation in the paediatric population. Post-mortem study from Sweden reported 
incidence of myocarditis to be 1.06 % in 12.747 consecutive autopsies (Gravanis & Sternby, 
1991). Since the clinical presentation of myocarditis is so variable, high index of suspicion 
is essential. Patients are asymptomatic and diagnosis is incidental in the majority of cases. 
The spectrum of disease ranges from nonspecific findings (chest pain, fever, myalgia, 
atrial or ventricular tachycardia) to acute heart failure and sudden death. Myocarditis as a 
cause of sudden death has been reported in up to 12% of young adults (Doolan et al., 
2004). However, population based study from Finland (Kyto et al, 2007) documented that 
the incidence of fatal myocarditis (1.59 per 100000) was highest in infants under one year 
of age and incidence was lowest in young adults (5-24 years, 0.12-0.17/100000). Recently, 
Weber et al have also suggested that myocarditis is an infrequent, corresponding to 
approximately 2% of paediatric deaths (Weber et al., 2008).        
Previous researches (Felker et al, 1999 & Lipshultz et al, 2003) strongly suggested that acute 
myocarditis may proceed to dilated cardiomyopathy. Diagnostic evaluation of a series of 
1.278 patients (mean age: 50 years, range 15-87 years) with cardiomyopathy revealed that 
9.8% of cases was diagnosed with myocarditis (Felker et al, 1999). In a paediatric study 
assessing the incidence of cardiomyopathy, viral myocarditis was found to be responsible 
for 27% of cases with dilated cardiomyopathy (Lipshultz et al, 2003). Moreover, in a 
prospective cohort study (Towbin et al, 2006), it has been shown that most common known 
cause of dilated cardiomyopathy is myocarditis (46%). Several mechanisms were postulated 
for progression of myocarditis to dilated cardiomyopathy, including direct viral injury, 
www.intechopen.com
 Myocarditis 
 
40
autoimmune response of body through the effects of lymphocytes, natural killer cells, 
cytokines and apoptotic cell death (Kawai, 1999).  
Diagnosis of acute myocarditis can be difficult owing to the lack of accepted and 
standardized criteria in addition to the nonspecific pattern of clinical presentation. The other 
issue hampered agreement on the most proper diagnostic criteria and documentation of 
cases, is  broad diversity of aetiologies associated with myocarditis (Dec et al, 1985). At 
present, diagnosis has been made by use of pathological classification, commonly referred to 
as Dallas criteria (Aretz et al, 1987). The identification of inflammatory infiltrate with or 
without myocardial cell necrosis on conventionally stained myocardial tissue biopsy 
specimens is essential for histological diagnosis. On the basis of these criteria, myocarditis is 
described as active or borderline myocarditis in accordance with the presence or absence, 
respectively, of myocardial necrosis. The inflammatory infiltrate should be further identified 
as lymphocytic, eosinophilic or granulomatous (Figure 1). Sampling error, low sensitivity 
and specificity, discrepancy in expert interpretation remain limitations to the use of 
endomyocardial biopsy for diagnosis of acute myocarditis (Hauck et al, 1989 & Shanes et al, 
1987). Inflammation in acute myocarditis may be focal, therefore it is challenging to biopsy 
the inflamed area of myocardium (Robinson et al, 2005). Additionally, it is invasive and 
potentially dangerous procedure, particularly in the paediatric patient (Checchia & Kulik, 
2006). According to the some researchers (Parillo, 2001), this histopathological criteria could 
not be considered the gold standard for diagnosing acute myocarditis. Molecular 
pathological analyses, such as polymerase chain reaction (PCR) and in-situ hybridization 
allows rapid detection and documentation of the viral genetic material in the myocardium 
(Angelini et al, 2002 & Bock et al, 2010). In 2008, it was reported that immunohistological 
signs of myocarditis has been associated with poor outcome in myocarditis (Kindermann et 
al, 2008).   
 
 
Fig. 1. The pathological diagnosis of viral myocarditis necessitates the manifestation of a 
inflammatory infiltrate associated with myocyte necrosis. The infiltrate consists of 
predominantly mononuclear cells (Stained by hematoxylin and eosin, magnification X 400; 
Text and image courtesy of Ragip Ortac, Gulden Diniz, Malik Ergin)    
Therapy of myocarditis in children with inotropes and afterload reduction is usually 
sufficient. Although the long-term sequels are rare, dilated cardiomyopathy and sudden 
cardiac death may develop in clinical course. Extracorporeal membrane oxygenation and 
mechanical ventilations are other options for severe cases (Vashist & Singh, 2009). Newer 
therapeutic strategies such as intravenous immunoglobulin and immunosuppressive agents 
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have been investigated with the improvements in understanding pathogenesis of the 
myocarditis (Drucker et al, 1994 & Camargo et al 2009). It is the aim of this review to give a 
brief and complete discussion of pathogenesis, diagnosis and management of myocarditis.  
2. Etiology 
The vast majority of myocarditis in the developed countries result from viral infections 
(Table 1). The causes other than infections are autoimmune-systemic diseases, toxins and 
hypersensitivity to drugs (Brodison & Swann, 2001). Enteroviruses (particularly Coxsackie) 
and adenovirus were recognized as the major cause of viral myocarditis (Baboonian& 
Treasure, 1997; Pauschinger et al, 1999). During the last decade, parvovirus B19 (PVB19) and 
human herpesvirus 6 (HHV6) have been described as new pathogens (Kuhl et al, 2003). 
Moreover, investigators from Germany found that PVB19 and HHV6 are the most common 
causes of biopsy-confirmed viral myocarditis (Kuhl et al, 2005 & Mahrholdt et al, 2006). An 
investigation analysing the potential role of PVB19 in the clinical setting of acute 
myocarditis revealed that PVB19 was the most common agent. Kuhl et al had also noticed 
that Dallas criteria was frequently negative in patients with positive PVB19 PCR and 
macrophages were augmented in virus positive cases (Kuhl et al, 2003). These findings 
support the postulation of Bowles et al that different viruses have various pathogenic 
mechanisms such as lymphocyte-dependent vs. macrophage-dependent (Bowles et al, 2005). 
Nevertheless, PVB19 DNA has also been revealed in the myocardium of healthy donors 
(Donosa et al, 2005), in hearts of adults with dilated cardiomyopathy (Lotze et al, 2004), and 
in hearts of the patients with lupus and amyloidosis (Kuethe et al, 2007), despite the number 
of subjects studies was small. From these results, the question arises whether PVB19 
certainly cause the underlying heart disease or whether it is just spectator attending in the 
heart as a result of former infection which is usual in young adults or children. A study by 
Kuethe et al was conducted to investigate this question. They suggested that PVB19 displays 
lifelong persistence, identification of PVB19 DNA was not correlated with clinical symptoms 
and serological analysis should be standardized procedure for future studies considering 
prevalence of PVB19 (Kuethe et al, 2009).       
Polymerase chain reaction (PCR) analyses of myocardium in children and adult patients 
have showed the existence of adenoviral genome in cases with myocarditis and dilated 
cardiomyopathy with a larger frequency than enterovirus (Pauschinger et al, 1999 & Bowles 
et al, 2003). Geographical variation in viral etiology is also remarkable that hepatitis C virus 
has been more commonly documented in Japanese patients and parvovirus B19 is more 
frequently detected by PCR in German population (Magnani & Dec, 2006). Matsumori et al 
found that hepatitis C virus infection is often found in cases with dilated cardiomyopathy 
and that hepatitis C virus have an crucial role in the pathogenesis of cardiomyopathy 
(Matsumori et al, 1995). It was also suggested that antiviral therapeutics against hepatitis C 
virus could be indicated in these cases. Other viruses linked with myocarditis include 
Epstein-Barr virus, cytomegalovirus, herpes simplex virus, influenza A-B and HIV 
(Magnani & Dec, 2006). Multiple infections with different viruses have also been detected in 
cases (approximately one quarter of all cases) with systolic left ventricular dysfunction 
(Kuhl et al, 2005). Influenza A and B may also involve a combined myocarditis risk, 
particularly in patients with pre-existing cardiovascular diseases (Friman et al, 1995). From 
the study (Bowles et al, 2003) conducted in 624 patients with myocarditis (116 neonates, 191 
infants), it was concluded that most common amplified viral genomes in myocardial tissues 
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included are adenovirus, cytomegalovirus, parvovirus and influenza A (ordered in 
decreasing frequency). It has been known that HIV may cause myocarditis and dilated 
cardiomyopathy (Breuckman et al, 2005). Direct viral injury, antiretroviral agents, 
coinfections and inhibition of contractility through HIV glycoprotein type I 120 play a role in 
the pathogenesis of myocarditis and dilated cardiomyopathy (Chen et al, 2002). The 
introduction of highly active antiretroviral therapy (HAART) has significantly reduced the 
incidence of HIV related- myocarditis. On the other hand, in developing countries where the 
supply of HAART is limited, researchers have observed increase in prevalence of HIV 
associated cardiomyopathy (Pugliese et al, 2000).                 
 
Viral 
     Coxsackie virus            Respiratory syncytial virus 
     Adenovirus                   Vaccinia (smallpox vaccine) 
     Human herpes virus    HIV 
     Parvovirus B19             Influenza A and B 
     Hepatitis C virus          Cytomegalovirus 
     Epstein-Barr virus 
Bacterial 
     Borrelia Burgdorferi                  Streptoccus pneumoniae 
     Mycobacterial                            Treponema pallidum 
     Mycoplasma pneumonia          Neisseria Meningitides 
     Corynobacterium diphtheria    Rickettsia sp. 
     Hemophilus influenza              Vibrio cholerae  
Parasitic-Fungal-Protozoal 
    Ascaris sp.                              Schistosomiasis 
     Echinococcus granulosus      Larva migrans 
     Aspergillus sp.                       Candida 
     Taenia Solium                        Coccidioides 
     Cryptococcus                         Histoplasma  
     Toxoplasma gondium           Tryponosoma cruzi 
 Immunologic 
    Rheumatic fever                               Polymyositis, rheumatic arthritis 
    Chagas disease                                 Sarcoidosis 
    Systemic lupus erythamatosus        Thyrotoxicosis 
    Diabetes Mellitus                              Wegener’s Granulomatosis       
    Ulcerative colitis                               Scleroderma 
  Hypersensitivity-Drugs 
     Amitriptyline                   Amphotericin B          Arsenic         Scorpion envenomation  
     Anthracyclines                 Electric shock              Penicilline 
     Digoxin                             Phenytoin                    Copper 
     Dobutamine                     Colchicine                    Isoniazide   
     Cephalosporins                Iron                              Lead 
Table 1. Main etiologies observed in myocarditis. 
During the pandemic of influenza A (H1N1), myocarditis was documented in four children 
(80 children with H1N1 influenza) within a  30-day period (Bratincsak et al, 2010). In their 
retrospective review, three children had fulminant myocarditis, 1 with fatal outcome and 2 
www.intechopen.com
 Myocarditis in Childhood: An Update on Etiology, Diagnosis and Management 
 
43 
required extracorporeal membrane oxygenation support. From these findings, they assumed 
that new H1N1 influenza A virus is more frequently associated with a severe form of 
myocarditis that formerly encountered influenza strains. A study from Spain have also 
emphasized the importance of myocarditis as a risk factor for mortality.   
Numerous bacterial infections may cause myocarditis, involvement of myocardium may 
have insidious course (electrocardiography changes) or may present with significant signs 
and symptoms. Fulminant septicaemia may result in myocarditis with fatal course. Most 
common causes of myocarditis associated with bacteraemia included are meningococcus, 
streptococcus and Listeria (Brodison&Swann, 1998). Borrelia burgdorferi causes Lyme 
carditis with acute or chronic course. Recently,  a study o 207 children with early 
disseminated Lyme disease conducted by Costello et al found that 33 children (16%) had 
mild to fulminant myocarditis, 14 of whom had advanced atrioventricular block (none 
required permanent pacemaker). Lyme disease may rarely present with cardiomyopathy 
(Costello et al, 2009).         
Various drugs implicated in the development of myocarditis including; anthracyclins,  
cyclophosphamide, cisplatin, 5-fluorourasil, Lithium, aminophylline, catecholamines, 
antibiotics (penicillines, ), phenytoine and trastuzumab (Ellis&Disalvo, 2007). Myocyte 
injury may occur by direct toxic effect on heart or by provoking hypersensitivity reactions. 
Hypersensitivity reaction may be indicated fever, sinus tachycardia, peripheral eosinophilia 
and a rash that follows days to weeks after administration formerly well-accepted agent. 
Actually, it is not the drugs that heralds the reaction, but its metabolites (haptens) in the 
cases of hypersensitivity myocarditis. The pathological findings are indistinguishable and 
are independent of the drug involved. The inflammatory infiltrate predominantly  consists 
of eosinophils, and can be located in focal areas, or diffusely within the myocardium with 
slight or no sign of necrosis, or substitute fibrosis. If the grade of myocardial inflammation 
or necrosis is severe, arrhythmias or hemodynamic collapse may likely occur. Eosinophilic 
necrotising myocarditis is an extreme form of hypersensitivity myocarditis that promptly 
cause cardiovascular collapse. Eosinophilic myocarditis has been documented following 
administration dobutamine and vaccines (Tetanus, small pox).  
Systemic diseases that are related with active myocarditis include connective tissue diseases 
such as systemic lupus erythematosus, mixed connective tissue disease, systemic sclerosis, 
Churg-Strauss syndrome; celiac disease and Whipple’s disease. Protozoal, helmintic and 
parasitic infections may also present with eosinophilic myocarditis. Myocardial 
abnormalities in SLE is multifactorial with coronary vasculitis, valvulopathy, hypertension, 
immune injury and drugs are the major contributors. Myocardial abnormalities are common 
in autopsy patients. However, clinically apparent myocarditis occurs in  < 10 % of cases 
suggesting that the subclinical form is more frequent (Magnani&Dec, 2006).    
Further understanding the etiology of myocarditis will illicit more direct therapeutic 
approaches such as vaccine and antiviral agents. Although some antiviral agents as 
ribavirin, oseltamivir and acyclovir have had moderate effect on influenza, RSV 
pneumonitis and CMV disease, currently there is no specific therapy approved for 
Enteroviruses, parvovirus B 19 and adenovirus. But, other options may be worth 
considering. A historical example of a promising therapy for viral myocarditis and 
prevention of dilated cardiomyopathy is that of decline in the incidence of endocardial 
fibroelastosis in children after initiation of mumps virus vaccine. It has been known that 
endocardial fibroelastosis is associated with congestive heart failure and death. Evidence 
from myocardial samples of patients with EFE supported the hypothesis that it is sequela of  
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viral myocarditis, in particular of that due to mumps virus. Based on the chronology of the 
fading of the disease, Ni et al. suggested that it is likely that vaccination was responsible for 
the remarkable decrease in documented case of EFE. So it is logical to think that vaccination 
against parvovirus B19, echovirus and adenovirus could diminish cases of myocarditis and 
dilated cardiomyopathy.  
3. Pathogenesis  
Special attention to understanding the mechanism and pathogenesis of myocarditis have 
been increased since Gore and Saphir showed in 1947 that diphteric and rheumatic 
carditis separately comprised only 10% of a series of 1402 patients of myocarditis (Gore & 
Saphir, 1947). In 1970’s, several investigators demonstrated the persistence of neutralizing 
antibodies to coxsackie B (CVB) in cases with cardiomyopathy than healthy subjects 
(Kawai, 1971, Kawai et al., 1978, Toshima et al., 1979). This finding supported the 
hypothesis of a viral cause underlying the pathogenesis of cardiomyopathy. Evidence 
from murine models  helped understanding pathogenesis of myocarditis (Liu&Mason, 
2001). Myocarditis in susceptible mice is characterized by 3 separate disease processes, 
direct viral or other infectious agent access to myocardium tissue rapidly evolves into the 
second phase (Figure 2). In second phase, also called autoimmune phase of disease, 
immunological activation is the main feature. During the last phase, signs of myocarditis 
usually disappear and the damaged myocytes are  substituted by diffuse fibrosis. 
Misdiagnosis and inappropriate therapy are especially possible at the time of transitional 
period among the 3 phases. In the case of reinfection and autoimmune recurrence, 
confusion can be compounded.  
3.1 Viremia 
Currently, there are two models of coxsackie B virus 3 induced myocarditis. The first one 
provokes acute viral myocarditis with a significant damage to myocytes and sudden death 
of animals within a week of infection (Fuse et al., 2005). In the second model, some degree of 
mice seemed to advance acute viral myocarditis following an infection with a cardiotropic 
strain of CVB3 (Fairwather&Rose, 2007). There also models with CMV, HIV and adenovirus 
(O’Donoughe et al., 1990, Salone et al., 2003, Beischel et al., 2004). During the time of active 
viremia, cardiotropic RNA virus (Coxsackie B) is taken into cells by receptor mediated 
endocytosis and are directly translated interior to the cells to produce protein (Huber, 1993). 
The virus enters the cell by endothelial receptors, particularly coxsackie-adenovirus receptor 
(CAR). Additionally, coxsackie B1, B3 and B5 uses decay accelerating factor (Shafren et al., 
1995); adenoviruses uses  ǂv integrin as coreceptors for viral entry (Wickham et al., 1994). It 
has been shown that CAR is highly expressed in the heart and brain, peaking in the 
perinatal period with subsequently declining with age and it is identified on the entire 
surface of the myocardium (Kashimura et al., 2004). Therefore, one can explain the 
susceptibility of neonates and infants to coxsackie B 3 myocarditis on the basis of expression 
level and the location of CAR. Titers of viral antigens in the myocardium is highest on the 
fourth day of inoculation of virus (Tomioka et al., 1986). No neutralizing antibodies to the 
virus were present until day 4. The antibody titers elevate promptly on day 8 and 10 reach 
the highest level on day 14 (Kawai, 1999). The emergence of a rising antibody titers is closely 
linked to elimination of the virus from the myocardium.       
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Fig. 2. Schematic drawings of pathophysiological processes of viral myocarditis. NO: Nitric 
oxide, NK: Natural killer cells. 
3.2 Autoimmunity 
First phase terminates with the stimulation of the host immune response that weakens viral 
proliferation but may also augment viral entry. Under ideal circumstances, immune system 
should normalize to a resting state once viral proliferation is limited. However, if host 
immune system stimulation persists unrestricted even with the elimination of the virus, 
autoimmune disease may develop, activating the second phase. This phase is distinguished 
by inflammatory cellular infiltration with natural killer cells and macrophages, then 
consequent expression of proinflammatory cytokines, especially interleukin-1, interleukin-2, 
TNF and interferon Ǆ (Kawai, 1999, Matsumori et al., 1994). It has been shown that TNF 
triggers endothelial cells, recruits further inflammatory cells, more enhances cytokine 
production and has direct negative inotropic effects (Feldman&McNamara, 2000). Cytokines 
can also induce macrophages to express inducible nitric oxide synthase (NOS) in heart cells 
(Zaragoza et al., 1998). The role of NO in myocarditis is complicated. NO can reduce viral 
replication, and peroxynitrate production has strong antiviral effects (Zaragoza et al., 1997). 
Mice deficient in NOS were found to have greater viral titers and more widespread myocyte 
injury (Padalko et al., 2004). Alternatively, myosin induced autoimmune myocarditis animal 
model showed us that NOS expression in myocytes and macrophages is related with more 
severe inflammation, where NOS inhibitors can have potential to reduce myocarditis 
severity (Zaragoza et al., 1998, Mikami et al., 1997). Furthermore, improvement in 
myocarditis of the mouse model has been demonstrated by blocking IL-1b or TNF-a at the 
onset of the disease (Fairweather et al., 2004). Cihakova et al. also showed that the severity 
of CVB3 induced myocarditis as well as myosin-induced myocarditis is associated with the 
levels of IL-1b and IL-18 in the myocardium (Cihakova et al., 2008). T cells are activated in 
viral myocarditis by classical cell-mediated immunity. Viral peptide fragments are 
processed in the Golgi apparatus of the myocyte and presented to the cell. These prepared 
T-cells are capable of identifying the viral antigen and destroy the infected myocyte by 
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means of cytokine and perforine secretion (Ayach et al., 2003). But, persistent excited 
stimulation of the T cells is eventually harmful to the host, due to both direct T-cell 
mediated and cytokine-mediated  cell damage diminish the number of contractile elements.  
Continuous T-cell activation is induced through antigens intrinsic to the myocardium that 
share molecular mimicry with viral peptides. The virus may also prompt a TH2 reaction, 
stimulating more CD8 killer cells in the process. It can be explained partially by the presence 
of evidence that CD4/CD8 or p56lck knockout animals have a much better survival 
following coxsackie infection (Liu et al., 1995). Recently, it has been shown that CD4+ Th cell 
subset, referred as Th17 cells, are involved in several inflammatory diseases, including 
experimental autoimmune myocarditis and collagen induced arthritis (Aggarwal et al., 2003, 
Chen et al., 2006). In addition to the proinflammatory effects, evidence from previous works 
suggested that Th17 cells may facilitate the production of autoantibodies in the development 
of acute viral myocarditis (Yuan et al., 2009). In experimental study published last year 
(Yuan et al., 2010), they showed that IL-17 produced by Th17 may take part in the regulation 
of the equilibrium between antiviral immunity and autoimmunity in CAVB3-induce acute 
viral myocarditis and IL-17 will be a new therapeutic goal for viral myocarditis in future 
(Milenkovic et al., 2010). 
Although the activation of CD4 cells also leads to B-cell clonal expansion and antibody 
production, antibodies might not be the critical initiating factor that directs the advancing of 
the myocarditis. The severity of myocarditis was also found to be dependent on the 
responding T-cell subset in T-cell knockout mice (Opavsky et al., 1999). But, it has been 
shown that antibodies are a significant modifier of the disease phenotype. In a study 
conducted in 1982, it was found that among 30% of cases with suspected myocarditis, as 
well as in 18/19 patients with proven viral infection due to coxsackie, influenza A or 
mumps virus (Maisch et al., 1982). They also showed that antimyolemmal antibodies was 
correlated with the degree of in vitro induced cytolysis of rat myocytes.  
Adenoviral myocarditis differs from coxsackie virus in the setting of pathogenesis 
(Hayder&Müllbacher, 1996). The amount of CD2, CD3 and CD45ROt lymphocytes detected 
in the adenovirus-infected cases was decreased compared with those patients who had 
myocarditis with other pathogens (Pauschinger et al., 1999). It was also demonstrated that 
71% of PCR-positive adenoviral did not have inflammation histologically (Martin et al., 
1994). One of the strategies of adenovirus for modulating immune response is that 
interaction of adenoviral encoded proteins with host immune components. These proteins 
may protect cells from tumor necrosis factor mediated lysis, as well as downregulation of 
major histocompatibility complex class I antigen expression. On the other side, adenoviral 
E1a encoded proteins are able to encourage the induction of apoptosis and inhibition of 
interleukin-6 (IL-6) expression (Davison et al., 2003). Besides this, it restricts IL-6 signal 
transduction pathways. These functions of E1A may be relevant to the occurrence of dilated 
cardiomyopathy. HIV has been identified within myocytes and is related with interference 
of myocyte integrity and replacement of endocardial fibrosis. Therefore, it was suggested 
that HIV myocarditis may share similar pathogenic mechanism of those of coxsackie 
(d’Amati et al., 2001). 
It should be underlined that the natural killer (NK) cells is also important in the 
pathogenesis of myocardial inflammation. These finding corroborate those observed in a 
prior animal study, in which animals depleted of their NK cells previous to infection with 
coxsackievirus develop a more severe myocarditis (Godeny et al., 1987). The NK cells 
particularly reduce the nonenveloped virus infection by destroying the infected cells.  
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3.3 Dilated cardiomyopathy  
Several remodelling mechanisms leading to dilated cardiomyopathy may be particular to 
myocarditis. The association of myocarditis to dilated cardiomyopathy has been moderately 
elucidated by molecular techniques. Badorff and Knowlton, demonstrated that dystrophin is 
cellular target for coxsackie B3 viral protease (Badorrff&Knowlton, 1999). It may provide 
one of the molecular mechanisms clarifying the significant ventricular dilatation that may 
develop immediately following viral infection. Furthermore, it was found that dystrophin 
deficiency augments host vulnerability to coxsackie virus infection (Xiong et al., 2002). This 
conclusion may result from the findings that more efficient liberation of the virus from the 
infected myocytes and is related with an increase in virus-mediated cytopathic effects. 
Proteases from other viruses (adenovirus and HIV) may also cleave cytoskeletal proteins 
(Chen et al., 1999, Shoeman et al., 1993).  
Identification of viral RNA at early, intermediate and late stages of myocarditis has been 
demonstrated in animal models. That persistent myocyte viral gene expression may be a 
cause of progressive dilated cardiomyopathy. Some findings propose that the persisting 
viral RNA seems to be capable of replication. In 172 patients with biopsy-confirmed viral 
infection, persistent viral genome of enterovirus, parvovirus B19, and HHV-6 was found to 
be associated with on-going impairment in ejection fraction (Kuhl et al., 2005); But, in the 
lack of measurable virus titers, it appears likely that the replication can be done in a limited 
or transformed manner (Klingel et al., 1992). All the more so, such replication might produce 
novel antigenic non-infectious or defective interfering viral elements, sufficient to cause 
evolving myocardial injury (Kawai, 1999). Cytokines possibly will participate in the 
development of dilated cardiomyopathy (Ono et al., 1998). During the second phase, they 
stimulate the matrix metalloproteinases, such as elastase, colleganases and gelatinase. 
Moreover, various reports suggest that several different viruses perform as a trigger for 
apoptosis. In addition to an immune-mediated mechanism activated by viral infection and 
persistent viral RNA in the myocardium, apoptosis may provide the third mechanism to 
elucidate the development of dilated cardiomyopathy.  
3.4 Host factors 
It is not fully understood which factors may define susceptibility to viral myocarditis and 
the development of cardiomyopathy. There are still remaining issues to be answered as why 
is it that who are in proximity to each other may be infected with the identical virus, but all 
do not develop myocardial injury? Why do certain infected cases continue to develop mild 
versus severe myocarditis or cardiomyopathy. But, up to date, the presence of genetic and 
environmental factors have been documented that influence particularly to viral 
myocarditis. Risk factors associated with severe myocarditis include age, viral variant, 
exercise, mouse strain and sex (Woodruff, 1980). Biochemical alterations such as selenium 
deficiency, vitamin E deficiency (Beck et al., 2003) and mercury exposure (Illback et al., 1996) 
have been documented to increase the viral virulence. Host genetic configuration not only 
influences the pathogenic mechanism of disease but also affects the severity of myocarditis. 
HLA-DQ locus and CD45 polymorphisms were to found to be essential determinants for 
early viral infection (Tchilian et al., 2006).  Several investigations documented the significant 
association between dilated cardiomyopathy and MHC class II antigens, primarily HLA 
DR4 (Carlquist et al., 1991, Limas&Limas, 1989). In the study published in the Annals of 
Human Genetics,  it is documented that HLA-DQA1* 0501 and DQB1*0303 are related to 
genetic susceptibility to idiopathic dilated cardiomyopathy (IDC), while DQA1* 0201, DQB1* 
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0502 and DQB1* 0504 present protection from IDC (Liu et al., 2005). However, associations 
of MHC class II alleles with  dilated cardiomyopathy are possibly affected by ethnicity, sex, 
age and geographical variations. Besides the MHC haplotype, non- MHC genes should be 
considered (Neu et al., 1987). Two non-MHC loci on murine chromosomes 1 and 6, referred 
as Eam1 and Eam2, respectively, might influence autoimmune myocarditis (Guler et al., 
2005). These loci intersect with loci implicated in other autoimmune diseases, such as lupus 
and diabetes, might give a clue that various autoimmune disease could be controlled by 
related genetic mechanisms. Initial antiviral response by the host has been recognized to be 
mediated at least in part by Toll-like receptors. TLR3 was found to play a significant role in 
the host innate immune response to infection with several cardiotropic viruses. Recent data 
suggests that variations in TLR3 alter the innate immune response and might change host 
susceptibility to increased cardiovascular pathology (Gorbea et al., 2010).     
4. Clinical features  
As stated previously, clinical picture of myocarditis is extremely variable, ranging from 
asymptomatic ECG abnormalities to heart failure (Dec et al., 1985, Bowles et al., 2003). The 
term ‘’Acute fulminant myocarditis’’ is used for cases with severe congestive heart failure or 
cardiogenic shock (Amabile et al., 2006). Age of child influences clinical presentation of 
myocarditis (Dec et al., 1985). Viral prodrome of flu-like illness, respiratory symptoms or 
gastroenteritis may precede symptoms of heart failure. Neonates and infants present with 
poor feeding, irritability or listlessness, diaphoresis, apnea and episodic pallor. Usual 
symptoms of congestive heart failure, as well as mild cyanosis and pallor are observed on 
physical examination. It should be emphasized that neonates and affected younger infants 
may have intrauterine myocarditis with chronic course (Bowles et al., 2003). For very young 
infants acquiring myocarditis in the peripartal period, the prognosis is very poor, with more 
than 90% of children dying. Previous studies have implicated the myocarditis as the cause of 
sudden death (Friedman et al., 1998, Bowles et al., 2003). In the retrospective study of Krous 
et al., they evaluated the infants who died of sudden death infant syndrome in a safe sleep 
environment, accidental suffocation or myocarditis were assessed, and they have noticed the 
manifestation of scattered inflammatory cells and necrotic myocyte were noticed (Krous et 
al., 2009). From this observation, they suggested that few scattered inflammation and 
necrotic myocyte were normal finding in the developing heart exposed to new 
environmental pathogens. However, degree of cardiac infiltration was found to be greater in 
infants who died of myocarditis. In German study published in 2004, researchers found that 
viral myocardial affection is the cause of death in cases with SIDS (Dettmeyer et al., 2004). 
Besides, it was proposed by authors that PVB19 seems to play a more significant role than 
presumed so far.      
Recent history of viral disease 10 to 14 days preceding presentation typically occurs in older 
children and adolescents (Friedman et al., 1998). Nonspecific gastrointestinal and 
respiratory complaints are more common than chest pain (Vashist&Singh, 2009). Jugular 
venous distension and pulmonary rales may be seen, and the resting tachycardia may be 
obvious, unlike in neonates. Since symptoms of myocarditis vary considerably in children, 
diagnosis can be challenging. Durani and colleagues, documented that most patients present 
with complaints of shortness of breath having tachypnea at presentation (Durani et al., 
2009). Vomiting (48%) and poor feeding (40%) are also commonly seen in myocarditis. The 
authors also observed that the diagnosis of myocarditis was missed on the first presentation 
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to a physician in 83% of cases. In a retrospective review, of 31 children with probable and 
definite myocarditis, 57% were initially diagnosed as suffering pneumonia or asthma 
(Freedman et al., 2007). One point that deserves attention in these studies is the absence of  
other signs of congestive heart failure in the majority of cases with myocarditis. Only 50% of 
children had hepatomegaly and 34% had abnormal chest radiography. The 
electrocardiographic changes include sinus tachycardia with low voltage QRS complexes, 
inverted T waves  typically occur in the clinical setting of myocarditis (Durani et al., 2009). 
Wide Q waves and ST segment changes as a pattern of myocardial infarction also may be 
observed. Supraventricular tachycardia, ventricular tachycardia or atrial fibrillation, as well 
as atrioventricular block may occur (Friedman et al., 1994). Of note, the sensitivity of 
electrocardiography in myocarditis is only 47% (Morgera et al., 1992). However, Freedman 
and colleagues found that sensitivity of electrocardiography as a screening test was 93% 
(Freedman et al., 2007). Additional interesting finding that is worth to mentioning that the 
presence of axis deviation (%37) in children with myocarditis. Although ventricular 
tachycardia is a rare initial manifestation of myocarditis, it may often develops in long-term 
follow up and may occasionally result in sudden death (Drory et al., 1991).  
Myocarditis imitating an acute coronary syndrome has also been defined. Viral genomes 
were demonstrated in 71% of adult cases with normal coronary anatomy, clinically 
mimicking myocardial infarction. Parvovirus B19 was most common agent identified in this 
study (Kuhl et al., 2003). ECG criteria (wide Q waves in I, avL, V5 and V6, ST segment 
change > 2 mm, ventricular arrhythmias) was described for the diagnosis of myocardial 
infarction in children (Towbin et al., 1992). However, similar ECG findings can occur in 
myocarditis (Durani et al., 2009). Most common ECG findings in adult patients with 
myocarditis include ST segment elevation(55%), T wave inversion (27%), ST segment 
depression (27%)  and pathological Q waves (%18) (Dec et al., 1992, Angelini et al., 2000). 
Myocardial infarction and myocarditis in neonates overlap and mimic each other (deVetten 
et al., 2011). Despite angiographically normal coronary anatomy, global or segmental wall 
motion abnormalities are commonly obvious (Angelini et al., 2000). Physicians should 
always bear in mind the possibility of acute myocarditis in younger cases who present with 
acute coronary syndromes when coronary risk factors are lacking, global rather than 
segmental left ventricular dysfunction is evident on echocardiography or ECG abnormalities 
encompass beyond a single coronary artery zone (Magnani&Dec, 2006).  
5. Diagnosis        
Although the misdiagnosis of the myocarditis is common, several diagnostic methods can 
aid physicians in making diagnosis of the myocarditis.  
 
 
Fig. 3. 12 lead ECG in children with myocarditis. Negative T wave in DI, aVL, ST-T changes 
were noted in precordial leads. 
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5.1 Electrocardiography and chest radiography  
Chest radiography and electrocardiography (ECG) can be used as first line diagnostic 
modality (Figure 3). Most common ECG changes are sinus tachycardia, axis deviation, 
ventricular hypertrophy and ST-T wave changes (Freedman et al., 2007). Moreover, 
evidence from previous studies suggests that the presence of northwest axis deviation, new 
left bundle branch block and abnormal QRS complexes is correlated with higher rates of 
transplantation or death (Magnani et al., 2006, Morgera et al.,1992, Nakashima et al., 1998, 
Greenwood et al. 1976). A recent adult study have shown that QRS prolongation is an 
independent predictor for transplantation or death in patients with suspected myocarditis 
(Ukena et al., 2011). In the majority of cases of myocarditis (up to 90%), abnormal chest 
radiography was documented (Durani et al., 2009, Freedman et al., 2007). Most common 
chest radiography finding is cardiomegaly, followed by pulmonary edema and pulmonary 
infiltrate (Figure 4). 
 
 
Fig. 4. M-mode echocardiography (a) and chest x-ray (b) of an adolescent girl with 
presumed viral myocarditis. M-mode echocardiography demonstrating systolic dysfunction 
with flattened interventricular septum. In chest radiography, there was prominent diffuse 
vascular congestion that is compatible with pulmonary edema. 13 year old girl admitted our 
hospital with dyspnea and tachycardia. She had a history of preceding viral upper 
respiratory infection. The patient intubated and connected to mechanical ventilation on day 
one of emergency room admission. She died within 72 hours after initial presentation.  
5.2 Laboratory finding  
General markers for inflammation such as erythrocyte sedimentation rate and C-reactive 
protein in serum are commonly elevated. However, their usage in diagnosis of myocarditis 
is limited. Freedman et al. demonstrated that the most sensitive marker for myocarditis was 
an increased aspartate transaminase (AST). AST elevation was found in 85% of probable and 
definite cases of myocarditis (Freedman et al., 2007). On the other hand, C-reactive protein 
and erythrocyte sedimentation rate have been elevated in cases of myocarditis with a range 
of 27 to 56%. Cardiac troponin t (cTnT) has also been investigated as a diagnostic marker for 
acute myocarditis since 1990’s. cTnT, a contractile protein unique to cardiac muscle, is vastly 
concentrated in the myocytes and will be released into the blood within hours after heart 
muscle injury. Following myocardial cell necrosis an increased concentration of cTnT is 
noticable in blood for more than a week. Cardiac troponin T measurements are especially 
useful in clinical settings in which traditional enzyme determinations fail to diagnose 
myocardial cell damage effectively. Likewise, cTnT is not reliably corresponded to increases 
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in blood of cardiac enzymes or myoglobin in all cases of Wolff-Parkinson-White syndrome 
undergoing radiofrequency ablation. Cardiac troponin I, subunit of thin filament of 
contractile element of the myocardium, has high specificity (89%) and low sensitivity (34%) 
in adult patients with acute myocarditis, whereas cTnT has been documented to have a 
specificity of 83% and sensitivity of 71% in children. Moreover, higher levels of cTnT have 
been demonstrated to be a prognostic marker for poor outcome in adults presenting with 
acute myocarditis. Elevated levels of interleukin-10 (IL-10) and TNF appears to be predictor 
of fulminant myocarditis. Besides this, increase of serum Fas and Fas ligand levels, as well 
as immunohistological signs of inflammation (CD3 and/or CD68) on initial presentation are 
associated with fatal outcome in patients with acute myocarditis.    
5.3 Echocardiography   
Echocardiographic features of myocarditis are nonspecific. Patterns of echocardiography in 
myocarditis could mimic hypertrophic, dilated or right ventricular cardiomyopathy and as 
well as ischemic heart disease (Checcia&Kulik, 2006). Echocardiography can be used for 
assessing wall thickness, cardiac chamber size together with systolic and diastolic functions. 
Right ventricular dysfunction is relatively unusual. However, right ventricular dysfunction 
was found to be predictor of adverse outcome in patients with active myocarditis (Mendes 
et al., 1994). Left ventricular diastolic dysfunction with a restrictive pattern is also observed 
in most cases of myocarditis. Left ventricular wall thickening was found to be highest on 
days 1-3 after onset of acute myocarditis. It has also been noted that left ventricular 
thickening was more marked in the fulminant myocarditis (Felker et al., 2006). On the 
contrary to adult patients, echocardiographic findings of pediatric patients revealed that 
relatively thicker posterior wall was correlated with better prognosis and recovery 
(Carvalho et al., 1996). Segmental wall motion abnormalities are relatively frequent, but 
global hypokinesis is prevalent. Pericardial effusion commonly occurs. The presence of 
thrombi in ventricle has also been documented in up to 25% of cases (Daly et al., 1983).    
 
 
Fig. 5. Cardiac magnetic resonance imaging of acute myocarditis in a adolescent. In four 
chamber and short axis view, subepicardial late enhancement are noted. Text and image 
courtesy of Alper Yuksel, Yigit Goktay.  
5.4 Magnetic resonance imaging  
Current practice has focused on the use of cardiac magnetic resonance imaging (CMR) for 
the diagnosis of acute myocarditis (Gutberlet et al., 2008, Friedrich et al., 1998). CMR with a 
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unique potential for tissue characterization, particularly with the utilization of T1 and T2 
weighted images, can assess 3 markers of tissue injury, which is, hyperemia and capillary 
leakage, necrosis and fibrosis and intracellular and interstitial edema (Friedrich et al., 2009). 
CMR visualizes  the entire myocardium, recognizing borders of inflammation from later 
modeling. Thus, it can be used to monitor lesions and be used to show the execution of 
endomyocardial biopsy, as well as it may be useful in the  quantification of the magnitude of 
damage (Danti et al., 2009, Mahroldt et al., 2004). Goitein et al. demonstrated that cardiac 
MRI have a larger impact than echocardiography in verifying the existence of myocarditis 
and evaluating the extent of disease (Goitein et al., 2009). It has been shown that 
echocardiography is useful in revealing wall motion abnormalities, whereas cardiac MRI 
could actually identify the often subtle patchy myocardial inflammation (Friedrich et al., 
1998). Gadolinium is used as a contrast agent due to ability to penetrate cells whose 
membranes ruptured and allows contrast agent to diffuse into the cells (Weinmann et al., 
1984). Myocardial blood flow and edema, that is likely to be increased in tissues which are 
inflamed, could augment signal enhancement in MRI. But, cardiac MRI features can be 
missed on the first pass perfusion (Skouri et al., 2006). Delayed enhancement MRI  permits 
visualization of necrotic and fibrotic myocardium (Friedrich et al., 2009). The observations 
obtained from the studies using contrast media-enhanced cardiac MRI indicate that pattern 
of myocarditic lesions occur predominantly in the lateral free wall and get localized to the 
subepicardial or intramyocardial regions (Mahroldt et al., 2004, Friedrich et al., 1998). The 
finding of lateral free wall involvement (subepicardial region) partially explain why some 
young patients with acute myocarditis can present with only  ST elevation on ECG (Figure 
5). Postmortem studies also showed that lateral wall was the preferred location in 
myocarditis (Theleman et al., 2001, Shirani et al., 1993). Subendocardial region involvement 
pattern which is typical for myocardial infarction was never seen in patients with acute 
myocarditis (Mahroldt et al., 2004). Mahroldt et al. also demonstrated that in the right 
ventricle half of septum, that is common location of EMB, had relatively low density of 
inflammatory cells. Apart from lateral free wall pattern, Marhold et al showed that HHV6 
myocarditis had  pattern that was located in midwall area of the interventricular septum. 
Pericardial effusion has also been reported in 32 to 57% of cases with myocarditis (Friedrich 
et al., 2009). Its presence, although not specific for myocarditis, is a supportive evidence for 
active inflammation.  
Recently, International Consensus Group on Cardiovascular Magnetic Resonance suggested 
the diagnostic criteria, known as ‘’Lake Louis Consensus Criteria’’ (Friedrich et al., 2009). 
Cardiac MRI should be made in the setting of clinically suspected myocarditis according to 
these criteria. It was also stated that maximum diagnostic accuracy can be accomplished 
with the presence of any two or more of the following criteria: Regional or global 
myocarditis signal increases in T2 weighted images, increased global myocardial early 
gadolinium enhancement ratio between myocardium and skeletal muscle (T1 weighted 
images) or presence of at least one focal lesion with nonischemic regional distribution (late 
gadolinium enhancement).   
In a retrospective study published in 2009, researchers found that myocarditis in children is 
characterized mainly by subepicardial and transmural enhancement. Global hypokinesia, 
left ventricular dilatation, ejection fraction less than 30% and transmural myocardial 
involvement were  discovered to be associated with poor outcome (Vashist et al., 2009). 
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5.5 Biopsy  
Despite its limitations, EMB is the gold standard for diagnosis of myocarditis. Together with 
simultaneous PCR and immunohistology, rapid detection of the viral genome is possible 
(Checcia&Kulik, 2006). The Dallas criteria have regulated the definition of myocarditis 
(Aretz et al., 1987). Active myocarditis is considered if light microscopy shows infiltrating 
lymphocytes and cytolysis. One of the potential advantage of this procedure it may aid 
physician in determining the management  of myocarditis. Children with viral myocarditis 
may benefit from therapy with immune suppression while patients with cardiomyopathy 
may not (Liu et al., 2001). Several issues have to be considered before making a decision 
about biopsy. As stated earlier, some complications such as pneumothorax, dysrhythmia, 
perforation and death, may occur during the procedure, and it can be hazardous for 
particularly pediatric patients (Pophal et al., 1999). Limited sensitivity of EMB that is related 
with sampling error should also be evaluated (Hauck et al., 1989). Substantial controversy 
exist with respect to diagnostic criteria for examining tissue specimens. Poor interobserver 
variability may limit the utility of Dallas criteria (Shanes et al., 1987). A scientific statement 
from the American Heart Association, The American College of Cardiology and European 
Society of Cardiology published in 2007, has evaluated the role of EMB in myocarditis 
(Cooper et al.,  2007). Various clinical scenarios have been described. Of these only two  
have received class I recommendation for EMB (Table). In a retrospective review analyzing 
the morbidity and mortality of EMB in children, highest risk was found in children with 
suspected myocarditis on inotropic support (Pophal et al., 1999). Authors also found that 
risk of biopsy in small children (< 10 kg) or sick infants was extreme. Compared with 
established risk of EMB in adults, there is an increased risk in children. Thus, careful risk-
benefit analysis should be therefore undertaken for each patient.      
6. Treatment            
In spite of the significant progress in understanding the mechanisms of myocarditis 
pathogenesis in last two decades, advances in treatment strategies are still limited and the 
supportive care is the principal therapy. Most patients with acute myocarditis presenting 
with dilated cardiomyopathy respond favorably to standard anticongestive therapy 
including afterload reduction, diuretics, angiotensin converting enzyme inhibitors and the 
introduction of  ǃ blockers such as carvedilol or metoprolol succinate once the acute phase is 
controlled. Various experimental studies with ǃ adrenoreceptor inhibitors or agonists 
showed different effects in acute myocarditis. Treatment with propranolol in mice infected 
with encephalomyocarditis virus (EMCV) reduced the severity of myocarditis and mortality 
(Wang et al., 2005). On the other hand, carvedilol, non-selective ǃ blocker, improved the 
survival and decreased the virus replication of mice infected with EMCV through the 
enhancement of IL-12 and IFN-Ǆ production, whereas metoprolol had no effect on this 
murine model (Nishio et al., 2003). Despite the lack of extensive studies in pediatric patients, 
administration of carvedilol has been found to be associated with improvement of left 
ventricle function and clinical symptoms and normalization of antioxidant enzyme activity 
(Bajcetic et al., 2008). Similar to effects of ǃ blockers, ACE inhibitors and angiotensin 
receptor blockers have been documented to lessen viral myocardial injury in murine models 
(Yamamoto et al., 2003). It is also proposed that early introduction of beta-blockers and ACE 
inhibitors might prevent the remodelling that advances to dilated cardiomyopathy 
(Ellis&DiSalvo, 2007). Phosphodiesterase inhibitors such as milrinone, if well tolerated, can 
www.intechopen.com
 Myocarditis 
 
54
be really helpful. A recent multi-institutional analysis revealed that milrinone was used 
most often for vasoactive support in children (Klugman et al., 2009). Anticoagulants should 
be considered if ejection fraction is severely decreased or in the setting of atrial arrhythmia 
(Gunthard et al., 2009). Digoxin should be used in low dose and with caution in patients 
with viral myocarditis since high dose digoxin was proven to increase mortality in animals 
with EMVC induced myocarditis as well as elevate intracardiac production of cytokines 
(Matsumori et al., 1999). Ventilation and oxygenation could be best achieved with 
continuous positive airway pressure (CPAP) or other non-invasive methods. CPAP, unloads 
inspiratory muscles and leads to decreased left ventricular afterload without compromising 
cardiac index via increasing intrathoracic pressure. Medications used for intubation can 
cause hypotension and acute cardiovascular collapse, thus CPAP  also avoids this and is an 
outstanding adjunctive therapy for cardiac failure and myocarditis (Bradley et al., 1992, 
Naughton et al., 1995).     
Extracorporeal membrane oxygenation support and ventricular assist device might be 
particularly useful for patients with fulminant myocarditis. Extracorporeal membrane 
oxygenation may also be considered in those who are in the recovery phase from acute 
myocarditis (Sezai et al., 2007). For patients with cardiogenic shock because of the acute 
myocarditis who worsen despite ideal medical therapy, extracorporeal membrane 
oxygenation and ventricular assist device may help as a bridge to transplant (Moloney et al., 
2005). The full mobilization, survival rates up to 90% for fulminant myocarditis and 
decreased anticoagulation make these pulsatile ventricular assist device systems as the 
alternative choice of therapy for children (Patopov et al., 2007). Cardiac transplantation is 
reserved only for patients who are intractable with medical management and mechanical 
circulatory support. Almost half of the annual cardiac transplantation cases are performed 
for idiopathic dilated cardiomyopathy, at least 10% of which represent as myocarditis 
(Ellis&DiSalvo, 2007).  
6.1 Immune therapy 
It is well known that the long term morbidity and mortality following viral myocarditis 
seem to be dependent on cellular and humoral immunity abnormalities. Therefore, many 
investigations have been conducted to search the use of immunosuppressants and immune-
modulator agents for treatment of acute myocarditis and dilated cardiomyopathy. However, 
debate still persists on whether immune therapy for acute myocarditis is useful or not. 
Initial adult studies investigating the effect of prednisone with or without azathioprine and 
cyclosporine demonstrated a slight improvement in left ventricular function. But, this 
improvement was temporary (Mason et al., 1995, Parillo et al., 1989).  In a study conducted 
by Parillo et al., patients were  grouped as reactive or nonreactive on the basis of 
histopathology, immunoglobulin deposition on EMB, an increased erythrocyte 
sedimentation rate or a positive gallium scan. At three months, reactive patients who were 
treated with prednisone (60 mg daily) had a statistically significant increase in ejection 
fraction compared with controls. After six months, improvement seen earlier was no longer 
present. In 1995, the Myocarditis Treatment Trial failed to show neither an improvement in 
left ventricle ejection fraction at 28 weeks nor an improvement in survival up to 4.3 years 
(Mason et al., 1995). Although a few uncontrolled studies showed benefit with several 
immune suppressive agents, meta analysis of adult studies did not confirm a significant 
favourable effect of immunosuppression (Garg et al., 1998, Maisch et al., 1998). There were 
also investigations to evaluate the results of immune suppressive regime in children with 
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acute myocarditis (Chan et al., 1991, Camargo et al., 1995). However, studies in children are 
inadequate and yet, no randomized controlled trials are present. In a study (Camargo et al., 
1995) conducted among 68 children with severe dilated cardiomyopathy, patients were 
classified into either conventional treatment or given one of three immune suppressive 
agents, prednisolone, prednisolone plus azathioprine and prednisolone with cyclosporine. 
Children taking immunosuppression treatment with a second agent, demonstrated 
enhanced hemodynamic parameters, as well as histological improvement in inflammation. 
A meta analysis (Hia et al., 2004) assessing the impact of immunosuppression on the 
outcome of acute myocarditis in children was published in 2004. Better outcome was 
observed among children who received immunosuppressive therapy. On the other hand, 
the findings were not statistically significant. Randomized large controlled studies are 
needed to conclude that immunosuppressive therapy is beneficial for outcome of children 
with acute myocarditis. On the contrary, one trial published in 1997, demonstrated that 
survival was improved with the treatment of cyclosporine and corticosteroids in patients 
with giant cell myocarditis (Cooper et al., 1997). A different approach has also been 
investigated, in which Wojnicz et al. used HLA expression on endomyocardial specimens to 
classify inflammatory cohort (Wojnicz et al., 2001). Of 202 patients with dilated 
cardiomyopathy, 84 patients with increased HLA expression were randomized to receive 
either placebo or immunosuppression for 3 months. After 2 years, significant improvement 
in ejection fraction and end diastolic diameter were noted only among the 
immunosuppressive group.  
It was suggested that intravenous immunoglobulin (IVIG) may be an useful therapy for 
acute myocarditis due to its both antiviral and immunomodulating effects. Previously, it has 
been shown that IVIG may be used in several autoimmune disorders, including idiopathic 
thrombocytopenic purpura, systemic vasculitis and Kawasaki disease (Rosen et al., 1993, 
Wolf et al., 1996). Up to date, there are no randomized controlled studies evaluating the use 
of IVIG to treat the children with acute myocarditis. A systemic review conducted by 
Robinson et al., evaluated the use of intravenous immunoglobulin therapy in acute 
myocarditis in both adults and children (Robinson et al., 2005). They determined that 
intravenous immunoglobulin might be useful in the presence of ongoing or active infection 
which may be causing obstinate cardiac failure. In a study conducted in children with 
presumed viral myocarditis, high dose IVIG treatment was found to be associated with 
improved recovery of left ventricular function and with a tendency of better survival 
(Drucker et al., 1994). In adults, the results of a randomized clinical trail suggested that for 
patients with recent onset dilated cardiomyopathy, IVIG did not enhance an improvement 
in ejection fraction (McNamara et al., 2001). However, in this cohort, ejection fraction was 
increased considerably during follow-up and short term prognosis remained favourable. 
Despite the presence of several case reports indicating that adults treated with intravenous 
immunoglobulin reveal better cardiac function, Cochrane review of IVIG administration in 
myocarditis and dilated cardiomyopathy demonstrated no benefit in adults (McNamara et 
al., 1997, Tedeschi et al., 2002). On the other hand, little is known about the exact 
mechanisms responsible for potential benefits of IVIG in the therapy of patients with acute 
myocarditis. Several studies both in the clinical setting and experimental models  propose 
that immunoglobulin may reduce inflammatory cytokines that have direct negative 
inotropic effects and decrease the oxidative stress (Kishimoto et al., 2003).  
Numerous cases with myocarditis recover spontaneously. It is hard to know if the noted 
improvement is a consequence of therapy with IVIG or immunosuppression versus natural 
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course of the disease. Therefore, studies assessing immunomodulation and immune 
suppressive agents were problematic to decode into an applicable, routine treatment for 
children and adults with acute myocarditis. One should also consider that initiating agents 
for acute myocarditis and following clinical course may change from time to time and by 
geographic site. Although such a controversy remains to be settled, IVIG may be used only 
in selected pediatric patients with acute myocarditis.    
6.2 Antiviral treatment & vaccines  
While viral infection is the most frequent cause of myocarditis, it might be possible to think 
that vaccines and antiviral agents might be helpful in the treatment of myocarditis. It is 
obvious that studies using polymerase chain reaction identified viral genomes in patients 
with acute myocarditis (Bowles et al., 2003). Bu, there are a few studies which demonstrated 
that requirement for transplantation and mortality was not dependent on the presence of 
viral genome (Kindermann et al., 2008, Kuhl et al., 2005). So, many investigators suggested 
that the presence of viral antigens or nucleotides in the myocardium alone is not satisfactory 
to prove that the virus is the cause of myocarditis (Matsumori et al., 2007). Since the 
diagnosis of viral myocarditis is frequently challenging and the diagnostic approaches have 
not been established or standardised, the number of clinical trials for virus proven 
myocarditis is limited. For that reason, in order to investigate therapeutic and preventative 
methods for myocarditis, various animal models have been developed. Several promising 
new agents including peroxisome proliferator activated gamma receptor activator, 
rapamycine, pycogenol, SUNC8079 and mycophenol mofetil have been studied in murine 
models of myocarditis during the last decade (Komiyoshi et al., 2005, Ellis&DiSalvo, 2007, 
Matsumori, 2007). It has been demonstrated that these agents decrease the severity of 
myocarditis and improve cardiac function, blocks activation of NF-κ, blocks mRNA 
expression of key cytokines (IL-1, IL-6 and TNF) and stabilizes mast cell (Matsumori, 2007). 
Synergistic effect of IFN- ǂ and ribavirin has been demonstrated against both EMCV and 
coxsackie virus infection (Okada et al., 1992, Matsumori, 2007). IFN- ǃ has reported to be 
effective in  studies including small number of patients with left ventricular dysfunction 
whose biopsy specimens were positive for adenovirus or enterovirus (Kuhl et al., 2003). 
Although various strategies for the prevention of acute myocarditis have been studied in 
murine models, up to now, there have been no vaccination trial in humans. Vaccination 
against mumps, rubella, poliomyelitis, measles and influenza has made myocarditis 
consequent to these infections quite rare and increases the arguments on whether 
vaccination against other cardiotropic viruses might prevent myocarditis in the future. A 
classical example in this regard was supported by the study of EFE described previously (Ni 
et al., 1997). The mumps virus vaccine has entirely  eliminated this form of dilated 
cardiomyopathy. It is unlikely that antiviral vaccines to battle this disease will be improved 
in the near future due to low incidence of the disease. 
6.3 Physical activity 
Recommendations concerning physical activity affirm that all patients with presumed or 
definite myocarditis discontinue competitive sports and undergo a prudent convalescence 
period around six months after the onset of clinical manifestations. Athletes may return to 
sports activity if LV function, dimensions and wall motions return to normal, markers of 
inflammation in blood have resolved, 12-lead ECG has normalized and clinically relevant 
arrhythmias are absent on Holter ECG or graded exercise testing (Maron et al., 2005).  
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7. Outcome  
Prognosis of myocarditis is as changed as its clinical presentations. Although the fewer data 
are available on the natural history of myocarditis in children, it is proposed that the 
outcomes in pediatric patients presenting with acute heart failure secondary to acute 
myocarditis tends to be more positive than the prognosis with dilated cardiomyopathy 
(Drucker et al., 1994, Lee et al., 1999). In a retrospective analysis of 36 children with 
histologically proven lymphocytic myocarditis (Lee et al., 1999), excellent outcomes have 
been demonstrated in children with myocarditis, especially those surviving 72 hours after 
presentation. Gagliardi and colleagues, classified 114 children into three groups as acute 
myocarditis, borderline myocarditis and non-inflammatory cardiomyopathy according to 
histological analysis (Gagliardi et al., 2004). Best survival rate (97%) was found in acute 
myocarditis group. They suggested that this high long term survival rate of this cohort may 
be due to effect of short term immunosuppressive therapy. On the other hand, in a multi-
center study including children and adults, difference in outcomes between age groups was 
noted (Bowles et al., 2003). Survival rate for neonates and infants (33 and 45%, respectively) 
were significantly lower than the other groups. Survival rate was noted to be greatest in 
adolescent age group. A retrospective study involving 28 children with acute myocarditis, 
analysed the predictors of outcome. It was observed that ejection fraction < 30%, shortening 
fraction < 15%, left ventricle dilatation and moderate to severe mitral regurgitation at 
admission were associated with poor outcome (Kuhn et al., 2004). However, it was 
understood from the findings of adult trials that syncope, right ventricle dysfunction, 
elevated pulmonary artery pressure and advanced New York Heart Association functional 
class were predictors of increased probability of death or requirement for transplantation 
(Mendes et al, 1994, McCarthy et al., 2000, Magnani&Dec, 2006, Kindermann et al., 2008). 
Histological classification and severity of symptoms may also give a clue about prognosis. 
Giant cell myocarditis has a chance of 89% of death or transplantation. Surprisingly, acute 
fulminant myocarditis may have a better prognosis (Ellis & DiSalvo, 2007).   
In general, transplantation is needed in 1-8% of patients with acute myocarditis (Ellis & 
DiSalvo, 2007). In spite of severe disease at presentation, there is a probability of 
improvement. Patients should not be listed promptly unless recovery is believed extremely 
unlikely despite judicious management.   
8. Conclusion 
Myocarditis in children is challenging given a variety of clinical manifestations that may 
share common pediatric illnesses such as respiratory infections and gastrointestinal 
disorders. A high index suspicion is so vital in the diagnosis. With the introduction of new 
additional diagnostic modalities including cardiac magnetic resonance imaging and 
biomarkers, cases will be identified easily in the future that would have been formerly 
missed. Myocarditis causes dilated cardiomyopathy in a significant portion of children. 
Prognosis for cases with acute viral myocarditis is much better than cases with established 
cases of dilated cardiomyopathy. Therefore, prompt diagnosis and early effective supportive 
care are crucial. Even if, much improvement has been achieved in pathogenesis, diagnosis 
and treatment of myocarditis, many questions remain to be answered and indicate the 
necessity for additional investigations. 
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